Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1971 1
1974 3
1975 1
1976 2
1978 2
1979 2
1980 7
1981 1
1982 2
1983 4
1984 7
1985 4
1986 4
1987 1
1988 13
1989 4
1990 14
1991 7
1992 16
1993 18
1994 13
1995 16
1996 10
1997 14
1998 15
1999 19
2000 19
2001 27
2002 21
2003 29
2004 20
2005 33
2006 48
2007 50
2008 68
2009 63
2010 87
2011 155
2012 125
2013 147
2014 178
2015 171
2016 192
2017 200
2018 233
2019 288
2020 308
2021 410
2022 428
2023 451
2024 498
2025 521
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,439 results

Results by year

Filters applied: . Clear all
Page 1
Dravet syndrome.
Lagae L. Lagae L. Curr Opin Neurol. 2021 Apr 1;34(2):213-218. doi: 10.1097/WCO.0000000000000902. Curr Opin Neurol. 2021. PMID: 33395108 Review.
RECENT FINDINGS: Comprehensive guidelines for a more standardized treatment in children with Dravet syndrome have been published. First-line and second-line treatments actually include only a few antiseizure medications, such as valproate, clobazam, stiripentol …
RECENT FINDINGS: Comprehensive guidelines for a more standardized treatment in children with Dravet syndrome have been publish …
International consensus on diagnosis and management of Dravet syndrome.
Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, Wilmshurst J, Sullivan J. Wirrell EC, et al. Epilepsia. 2022 Jul;63(7):1761-1777. doi: 10.1111/epi.17274. Epub 2022 May 12. Epilepsia. 2022. PMID: 35490361 Free PMC article.
OBJECTIVE: This study was undertaken to gain consensus from experienced physicians and caregivers regarding optimal diagnosis and management of Dravet syndrome (DS), in the context of recently approved, DS-specific therapies and emerging disease-modifying treatments …
OBJECTIVE: This study was undertaken to gain consensus from experienced physicians and caregivers regarding optimal diagnosis and management …
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Nabbout R, et al. JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. JAMA Neurol. 2020. PMID: 31790543 Free PMC article. Clinical Trial.
IMPORTANCE: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure control with their current stiripentol-containing antiepileptic drug regimens. ...Eligible patients were children aged 2 …
IMPORTANCE: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have p …
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Guerrini R, et al. Epilepsia Open. 2024 Apr;9(2):689-703. doi: 10.1002/epi4.12923. Epub 2024 Mar 1. Epilepsia Open. 2024. PMID: 38427284 Free PMC article.
OBJECTIVES: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). ...The risk of discontinuations due to AEs was lower for stiripentol, although the stiripentol trials were shorter. S …
OBJECTIVES: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome …
Stiripentol for Dravet syndrome.
[No authors listed] [No authors listed] Aust Prescr. 2020 Jun;43(3):102. doi: 10.18773/austprescr.2020.029. Epub 2020 Apr 24. Aust Prescr. 2020. PMID: 32675915 Free PMC article. Review. No abstract available.
Genetic therapeutic advancements for Dravet Syndrome.
Chilcott E, Díaz JA, Bertram C, Berti M, Karda R. Chilcott E, et al. Epilepsy Behav. 2022 Jul;132:108741. doi: 10.1016/j.yebeh.2022.108741. Epub 2022 May 30. Epilepsy Behav. 2022. PMID: 35653814 Free article. Review.
Dravet Syndrome is a genetic epileptic syndrome characterized by severe and intractable seizures associated with cognitive, motor, and behavioral impairments. ...In this review, we summarize our current knowledge of novel genetic therapies that are currently under d …
Dravet Syndrome is a genetic epileptic syndrome characterized by severe and intractable seizures associated with cognitive, mo …
Stiripentol (Diacomit) for Dravet syndrome.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Mar 22;63(1620):e48-e50. Med Lett Drugs Ther. 2021. PMID: 33976090 Review. No abstract available.
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S, Trinka E, Russo E, Del Giovane C, Matricardi S, Meletti S, Striano P, Damavandi PT, Silvestrini M, Brigo F. Lattanzi S, et al. Drugs. 2023 Oct;83(15):1409-1424. doi: 10.1007/s40265-023-01936-y. Epub 2023 Sep 11. Drugs. 2023. PMID: 37695433 Free PMC article.
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. ...Stiripentol had a higher risk of AE occurrence than pharmaceutical-grade cannabidiol (OR 75.72, 95% CI 3.59-1598.58) …
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifel …
Dravet syndrome: Advances in etiology, clinical presentation, and treatment.
He Z, Li Y, Zhao X, Li B. He Z, et al. Epilepsy Res. 2022 Dec;188:107041. doi: 10.1016/j.eplepsyres.2022.107041. Epub 2022 Oct 29. Epilepsy Res. 2022. PMID: 36368227 Review.
Dravet syndrome (DS) is a form of genetic refractory epilepsy. More than 80 % of DS patients carry pathogenic SCN1A mutations, and this percentage is actually higher due to false-negative results in gene testing. ...The combination of valproic acid, clobazam and …
Dravet syndrome (DS) is a form of genetic refractory epilepsy. More than 80 % of DS patients carry pathogenic SCN1A mutations, …
Defining Dravet syndrome: An essential pre-requisite for precision medicine trials.
Li W, Schneider AL, Scheffer IE. Li W, et al. Epilepsia. 2021 Sep;62(9):2205-2217. doi: 10.1111/epi.17015. Epub 2021 Aug 2. Epilepsia. 2021. PMID: 34338318 Free PMC article.
Patients with SCN1A pathogenic variants were reviewed and only those with Dravet syndrome were included. Clinical data, including seizure and developmental course, were analyzed in all patients with SCN1A-Dravet syndrome. ...SIGNIFICANCE: An evidence-b …
Patients with SCN1A pathogenic variants were reviewed and only those with Dravet syndrome were included. Clinical data, includ …
4,439 results